Breast Carcinoma In Situ

This is a type of breast cancer where the abnormal cells are still contained within the milk ducts or lobules. It's considered non-invasive because the cancer hasn't spread outside these areas. It's often found during a mammogram and may need further testing or treatment.

Condition

What people with Breast Carcinoma In Situ report

Every report comes from a Lived member, sent anonymously.

Have you tried Tamoxifen for Breast Carcinoma In Situ?

NameHow it went

About Breast Carcinoma In Situ

What It Is

Breast carcinoma in situ means that abnormal cells resembling cancer cells are growing inside the lining of the breast's milk ducts or its milk-producing glands (lobules), but have not broken through into the surrounding breast tissue. "In situ" means "in its original place." While the cells stay contained, they cannot spread to lymph nodes or other parts of the body. There are two main forms, and they mean quite different things. Ductal carcinoma in situ (DCIS) starts in the milk ducts and makes up roughly one in five new breast cancer diagnoses in the United States. It is often called stage 0 or noninvasive breast cancer, although some health organizations prefer to call it a precancer. Either way, some DCIS would grow into invasive cancer if left alone, and no test can yet tell which, so it is usually treated. Lobular carcinoma in situ (LCIS) starts in the lobules. It is generally not considered cancer and typically does not turn into invasive cancer itself. Instead, it marks a higher chance of developing breast cancer in the future, in either breast. Paget disease of the nipple, in which cancer cells affect the skin of the nipple and the darker area around it, is also grouped here when no invasive cancer is found inside the breast (only DCIS, or nothing at all).

Causes & Risk Factors

Carcinoma in situ develops when breast cells acquire changes in their DNA that make them grow abnormally. In most people, the reason those changes happen is unknown. The known risk factors are largely the same as for breast cancer in general: older age, a personal or family history of breast cancer, inherited gene changes such as BRCA1 and BRCA2, dense breast tissue and earlier radiation to the chest. Longer lifetime exposure to estrogen also raises risk. That includes a first period at a young age, a late menopause, having a first child later in life or not at all, and taking menopausal hormone therapy. Obesity and drinking alcohol add to risk as well. These factors change the odds across large groups of people; they do not explain why a particular person developed DCIS or LCIS, and many people diagnosed have none of them.

How It's Diagnosed

Most DCIS causes no symptoms and is found on a screening mammogram, often as tiny clusters of calcium deposits (calcifications) that appear as white specks on the image. Less often it causes a lump or nipple discharge. LCIS usually cannot be felt or seen on a mammogram, so it is most often discovered by chance when tissue is removed to check something else nearby. Only a biopsy confirms the diagnosis. A small sample of tissue, usually taken with a needle, is examined under a microscope by a pathologist to see whether the abnormal cells are still contained or have started to invade. For DCIS, the report also gives the grade, a measure of how abnormal the cells look, and says whether the cells have hormone receptors, meaning they grow in response to estrogen or progesterone. Larger areas and higher grades are more likely to be hiding a small area of invasive cancer, and receptor status decides whether hormone therapy is an option. For LCIS, the report notes whether it is the common classic type or the pleomorphic or florid types, which look more abnormal and are more likely to grow. A red, scaly or crusting nipple can be checked with a small skin biopsy for Paget disease, along with breast imaging to look for disease deeper inside.

Treatment Options

For DCIS, treatment aims to remove the abnormal cells and lower the chance that cancer develops later. Most people can choose between a lumpectomy (breast-conserving surgery), which removes the abnormal area with a rim of normal tissue around it, and a mastectomy, which removes the whole breast. Long-term studies of early breast cancer show that lumpectomy with radiation gives the same survival as mastectomy, so the choice often depends on how large or widespread the DCIS is, whether the surgeon can get clear edges (margins) free of abnormal cells, and how a person feels about keeping the breast. Mastectomy is usually advised when DCIS is large or found in several separate areas, and breast reconstruction can be done at the same time or later. Lymph nodes usually do not need to be removed, although the surgeon may take the nearest underarm node (a sentinel lymph node biopsy) during a mastectomy or if invasive cancer is suspected. Radiation to the remaining breast usually follows a lumpectomy to lower the chance of DCIS or invasive cancer returning in that breast. Leaving out radiation is not standard, but it can be reasonable for some older people, people with other serious health problems, or small, low-grade DCIS removed with clear margins. Most people who have a mastectomy for DCIS do not need radiation. When DCIS has hormone receptors, taking a hormone therapy pill for five years can lower the risk of new DCIS or invasive cancer in either breast. Options are tamoxifen, which blocks estrogen's effect on breast cells, or, after menopause, an aromatase inhibitor such as anastrozole or exemestane, which lowers the amount of estrogen the body makes. Whether that benefit outweighs the side effects is a personal decision to make with the care team. Close monitoring instead of surgery for low-risk DCIS is being studied but is not yet standard. Classic LCIS usually needs no further treatment once it is diagnosed. If it was found on a needle biopsy, a surgeon may remove the area to make sure nothing more serious sits next to it, and pleomorphic or florid LCIS is generally removed completely. The main work with LCIS is managing future risk: closer screening and, for some people, a risk-reducing medicine. Tamoxifen or raloxifene (a similar estrogen-blocking drug approved for this use only after menopause), taken daily for five years, lowers breast cancer risk by about 40 percent overall. What that means for one person depends on how high their risk was to begin with. Both medicines can cause hot flashes and both raise the risk of blood clots in the legs or lungs. Tamoxifen also slightly raises the risk of uterine cancer in women over 50, so unusual vaginal bleeding or spotting while taking it should be reported to the prescriber. Tamoxifen, whether taken after DCIS or for LCIS, can harm a developing baby, so pregnancy should be avoided while taking it and for 2 months after stopping, using a nonhormonal method of birth control; anyone hoping to become pregnant should raise this before starting.

What to Expect

The outlook for DCIS is excellent. More than 98 percent of people diagnosed with it are alive five years later, most are cured by treatment, and it is less likely to come back than invasive breast cancer. Recovery depends mostly on the surgery chosen, and on whether radiation follows. Because new DCIS or invasive cancer can still appear later in either breast, regular checkups and imaging continue after treatment, and people on hormone therapy review its side effects with their team along the way. LCIS usually changes little in daily life, but the raised risk is lifelong and applies to both breasts. Women with LCIS have about 7 to 12 times the risk of developing invasive breast cancer compared with women without it. Follow-up usually means a breast exam every 6 to 12 months along with a yearly mammogram, and sometimes breast MRI (a scan that uses magnets rather than X-rays and is added to mammograms for some people at higher risk), especially when other risk factors are present. This closer watch is meant to find any cancer early, when it is most treatable.

When to Seek Help

See a doctor about any new breast change, even after a recent normal mammogram or after finishing treatment: a lump or thickening in the breast or armpit, nipple discharge (especially if it is bloody or comes from one breast only), a nipple that newly turns inward, dimpling or puckering of the skin, or a red, scaly or crusting nipple that does not heal. If you have been told you have LCIS or have been treated for DCIS and do not have a clear follow-up plan, ask your care team to set one up.

Questions to Ask Your Doctor

  1. 1.Is this DCIS or LCIS, and what did the pathology report show about grade, type and hormone receptors?
  2. 2.Given the size and grade of my DCIS, how do lumpectomy with radiation and mastectomy compare for me?
  3. 3.How much would hormone therapy or a risk-reducing medicine actually lower my risk, and what side effects should I weigh?
  4. 4.What screening and follow-up schedule should I have from now on, and would breast MRI help?
  5. 5.Should I have genetic counseling or a formal breast cancer risk assessment?

Last reviewed • Oct 2026

Educational content, not medical advice.